Navigation Links
Medarex Reports Phase 1/2 Clinical Data of MDX-060 in Lymphoma at American Association for Cancer Research Meeting
Date:4/16/2008

>Medarex Statement on Cautionary Factors

Except for the historical information presented herein, matters discussed herein relating to Phase 1/2 clinical data of MDX-060 in lymphoma may constitute forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Statements that are not historical facts, including statements preceded by, followed by, or that include the words "potential"; "may"; or similar statements are forward-looking statements. Medarex disclaims, however, any intent or obligation to update these forward-looking statements. Risks and uncertainties include risks associated with product development, unforeseen safety issues resulting from the administration of antibody products in humans, as well as risks detailed from time to time in Medarex's public disclosure filings with the U.S. Securities and Exchange Commission (SEC), including its Annual Report on Form 10-K for the fiscal year ended December 31, 2007 and its quarterly reports on Form 10-Q. There can be no assurance that future milestone payments will be paid, whether the product development efforts will succeed, or whether other developed products will receive required regulatory clearance or that, even if such regulatory clearance were received, such products would ultimately achieve commercial success. Copies of Medarex's public disclosure filings are available from its investor relations department.

Medarex(R), the Medarex logo and UltiMAb(R) are registered trademarks of Medarex, Inc. All rights are reserved.


'/>"/>
SOURCE Medarex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Medarex to Present at Thomas Weisel Partners Healthcare Conference 2007
2. Medarex to Present at the Bear Stearns 20th Annual Healthcare Conference
3. Medarex Announces Extension of Broad Antibody Development Relationship with Centocor
4. Medarex to Present at the A.G. Edwards 2nd Annual Emerging Growth Conference
5. Medarex to Present at the UBS Global Life Sciences Conference
6. Medarex Announces Election of Marc Rubin as New Board Member
7. Medarex to Present at the 26th Annual JPMorgan Healthcare Conference
8. Medarex Announces Completion of Sale of Shares in Genmab A/S
9. Medarex to Announce 2007 Fourth Quarter and Year-End Financial Results on Tuesday, February 26, 2008
10. Medarex to Present at the Susquehanna Financial Group Healthcare Conference
11. Medarex Announces Presentations at Annual Meeting of the American Association for Cancer Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... Grace Century portfolio project, Provia Laboratories , ... the Board, to the National Stem Cell Ethics Committee ... by the Ministry of Health on behalf of the Government ... More than a year after Bahamian Parliament passed the ... Christie said the government has completed the accompanying regulations and ...
(Date:10/30/2014)... , Oct. 30, 2014  Regado Biosciences, Inc. (Nasdaq: ... hold a conference call and live audio webcast on ... discuss its third quarter 2014 financial results. ... by dialing (888) 347-1165 for domestic callers or (412) ... webcast live under the investor relations section of the ...
(Date:10/27/2014)... 27, 2014 Ryan Carfley , Managing ... to sit down with Bryan Hamilton, the publisher of the ... discuss talent in the Research Triangle region of North Carolina. ... highlighted at the roundtable include the role of social ... of work/life balance and the unique role that Millennials play ...
(Date:10/27/2014)... and TORONTO , ... ( www.generex.com ) (OTCQB: GNBT) today announced two ... response triggered by its novel proprietary cancer immunotherapeutic ... in breast cancer patients. The AE37 cancer vaccine ... Antigen Express, Inc. ( www.antigenexpress.com ). The presentations ...
Breaking Biology Technology:Grace Century’s Stem Cell Biobank Project Announces Chairman’s Appointment to National Stem Cell Ethics Committee of The Bahamas 2Grace Century’s Stem Cell Biobank Project Announces Chairman’s Appointment to National Stem Cell Ethics Committee of The Bahamas 3Regado Biosciences to Provide Third Quarter 2014 Financial Results 2Personify's Ryan Carfley Talks Recruiting with Triangle Business Journal, RPG Solutions 2Personify's Ryan Carfley Talks Recruiting with Triangle Business Journal, RPG Solutions 3Generex Announces Presentations Correlating Immunological Response with Reduced Recurrence in Phase II Study of AE37 Breast Cancer Vaccine in Patients at the American College of Surgeons 2Generex Announces Presentations Correlating Immunological Response with Reduced Recurrence in Phase II Study of AE37 Breast Cancer Vaccine in Patients at the American College of Surgeons 3Generex Announces Presentations Correlating Immunological Response with Reduced Recurrence in Phase II Study of AE37 Breast Cancer Vaccine in Patients at the American College of Surgeons 4
... the price of soybean seed skyrocketing, soybean growers are looking for ... seeding rate. The research and education director of the North Central ... and profit potential in 2009. , ... Urbandale, Iowa ...
... (ASX: CYT) has today circulated a letter and ... shareholders. The letter provides an update on the ... 2009 and provides recommendations on how to vote ... 2009.(Photo: http://www.newscom.com/cgi-bin/prnh/20090225/NY75105 )The letter and the sample ...
... SEATTLE, Feb. 24 Implicit,Bioscience Ltd today announced ... Eli Lilly and Company. Implicit has paid an,undisclosed ... will also,receive a royalty on future IC14 sales. ... substantial expertise and passion to the,treatment of patients ...
Cached Biology Technology:NCSRP Research Director: "Earlier Planting can Increase Soybean Yields" 2NCSRP Research Director: "Earlier Planting can Increase Soybean Yields" 3Cytopia Letter to Progen Shareholders 2Cytopia Letter to Progen Shareholders 3Cytopia Letter to Progen Shareholders 4Cytopia Letter to Progen Shareholders 5Implicit Licenses Clinical Stage Antibody Program From Lilly 2Implicit Licenses Clinical Stage Antibody Program From Lilly 3
(Date:10/31/2014)... been studying the behavior of approximately 300 wild ... They observed that ravens slowly build alliances through ... they also observed that these affiliative interactions were ... about 50 % of the cases these interventions ... ravens, intervening can be potentially risky when the ...
(Date:10/30/2014)... Restoring wetlands can help reduce or reverse soil ... research in California,s Sacramento-San Joaquin River Delta by ... study, which is one of the first to ... methane as they cycle through wetlands, appears in ... . , Worldwide, agricultural drainage of organic ...
(Date:10/30/2014)... life, cells immediately begin accepting assignments to become a ... humans, are special. The cells of mammalian embryos get ... the protective placenta or to commit to forming the ... research from Michigan State University has revealed key discoveries. ... PLOS Genetics , provide insights into where ...
Breaking Biology News(10 mins):Dartmouth study finds restoring wetlands can lessen soil sinkage, greenhouse gas emissions 2Identifying the source of stem cells 2
... (NYSE: A) today introduced a high-performance ion trap ... life-science researchers to identify 60 to 80 percent ... such as protein identification and biomarker discovery, potentially ... cancer and speeding drug development efforts. The Agilent ...
... frequency of drug resistance in isolates of the AIDS ... urgent necessity. Host genes required to support the replication ... targets, but relatively few appropriate target genes have been ... conducted by Dr. Suzanne Sandmeyer and colleagues at the ...
... D. Anderson Cancer Center have developed a way to test ... chemotherapy drug Taxol are effectively killing tumor cells. They say ... to accurately assess whether patients are responding to these agents, ... , In two different studies being presented at the ...
Cached Biology News:Product improves peptide identification for proteomics research 2Study reveals candidate targets for anti-retroviral therapeutics 2Measuring Enzymes At End Of Cancer Pathway Predicts Outcome Of Tarceva, Taxol 2Measuring Enzymes At End Of Cancer Pathway Predicts Outcome Of Tarceva, Taxol 3
BD BioCoat Fibronectin 35 mm Culture Dishes, tissue-culture treated polystyrene with a uniform application of human fibronectin....
... a positive selection for creating baculovirus recombinants ... insect cells. The kit improves on the ... eliminating the time-consuming steps of plaque purification. ... with a portion of the essential open ...
... General description: Dish uses include large-scale colony-counting ... with PBA Flexys TM automated colony ... is a new product number, created to ... no availability yet, please order under the ...
Mouse monoclonal [7B9] to beta II Tubulin ( Abpromise for all tested applications). Antigen: Synthetic peptide, CEEEEGEDEA found at the c-terminus of beta II tubulin. Entrez GeneID: 10383 ...
Biology Products: